Emphysema: Elusive Target for Device Companies

Nearly a decade into the race to arm pulmonologists with interventional tools to treat emphysema, no clear winner is emerging. Emphasys, which had led the pack in developing a bronchial valve, hit a potential roadblock at the FDA. The question is whether competitors can fill the gap.

More from Archive

More from In Vivo